These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study.
    Author: Lorenz D, Hagen K, Ufer M, Cascorbi I, Deuschl G, Volkmann J.
    Journal: Neurology; 2006 Jun 13; 66(11):1753-5. PubMed ID: 16769957.
    Abstract:
    3,4-Diaminopyridine (3,4-DAP) is a potassium channel blocker that has recently demonstrated an antioscillatory effect in humans by significantly reducing downbeat nystagmus. Based on the presumed role of intrinsic oscillations in the pathophysiology of essential tremor (ET), the authors conducted a double-blind, placebo-controlled crossover study assessing the antitremor effect of a single dose of 3,4-DAP in 19 patients with ET. They did not find any significant change in tremor severity as measured by clinical ratings or accelerometry.
    [Abstract] [Full Text] [Related] [New Search]